The Patent Finder

Yeda Research and Development Co. Ltd.

284 patents currently held · Updated Nov 16, 2026
31 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 25 name spellings.

32
Ending by 2030
Dec 2026
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 6 fees due Dec 2 to 30, 2026 · next Dec 2
  • 2 fees due Jan 2 to 23, 2027 · next Jan 2
  • 5 fees due Feb 6 to 22, 2027 · next Feb 6
  • 3 fees due Mar 5 to 19, 2027 · next Mar 5
  • 10 fees due Apr 1 to 29, 2027 · next Apr 1
  • 4 fees due May 3 to 19, 2027 · next May 3
  • 9 fees due Jun 5 to 30, 2027 · next Jun 5
  • 8 fees due Jul 7 to 30, 2027 · next Jul 7
  • 10 fees due Aug 4 to 20, 2027 · next Aug 4
  • 5 fees due Sep 5 to 22, 2027 · next Sep 5
  • 8 fees due Oct 2 to 23, 2027 · next Oct 2
  • 2 fees due Nov 7 to 14, 2027 · next Nov 7

Which patents, and when each one lapses · Pro

Recent changes

  • 12 of the patents on this record were granted since Aug 18, 2026
  • 6 terms have ended since Aug 18, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 8,388,954Stabilising Formulation for Immunoglobulin G Compositions in Liquid Form and in Lyophilised Form
In force
 · High confidence
In forceHigh confidence
US 10,258,651Methods of Generating Glial and Neuronal Cells and Use of Same for the Treatment of Medical Conditions of the CNS
In force
 · High confidence
In forceHigh confidence
US 11,406,670Methods of Generating Glial and Neuronal Cells and Use of Same for the Treatment of Medical Conditions of the CNS
In force
 · High confidence
In forceHigh confidence
US 9,957,293Conjugates of RGD peptides and porphyrin or (bacterio)chlorophyll photosynthesizers and their uses
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,689,415Conjugates of RGD Peptides and (BACTERIO)CHLOROPHYLL Photosensitizers
In force
 · Medium confidence
In forceMedium confidence
US 7,947,672Water-Soluble Anionic Bacteriochlorophyll Derivatives and Their Uses
In force
 · Medium confidence
In forceMedium confidence
US 8,067,008Peptide Inhibitors for Mediating Stress Responses
In force
 · High confidence
In forceHigh confidence
US 9,631,175Methods of Generating Glial and Neuronal Cells and Use of Same for the Treatment of Medical Conditions of the CNS
In force
 · High confidence
In forceHigh confidence
US 11,326,147Redirected, Genetically-Engineered T Regulatory Cells and Their Use in Suppression of Autoimmune and Inflammatory Disease
In force
 · High confidence
In forceHigh confidence
US 8,486,653Antibodies and Pharmaceutical Compositions Containing Same Useful for Inhibiting Activity of Metalloproteins
In force
 · Medium confidence
In forceMedium confidence
10 of 284 patents shown.
Pro members see all 284.
Pro members: see all 284 patents
Also on record, not counted in the 284: 31 patents in force now held by others · 428 lapsed for an unpaid fee · 546 ended at full term · 1 past the fee grace period · 2 surrendered on reissue. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

125 pending · 365 abandoned · 55 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited